Detecting clinical change with the CDR-FTLD: differences between FTLD and AD dementia

Area of Science:

• Neurology
• Psychometrics
• Geriatric Psychiatry

Background:

• Frontotemporal lobar degeneration (FTLD) and Alzheimer's disease (AD) are distinct neurodegenerative conditions.
• Accurate assessment tools are crucial for differentiating disease progression and guiding patient care.
• The Clinical Dementia Scale-frontotemporal lobar degeneration (CDR-FTLD) is a potential instrument for evaluating dementia in FTLD.

Purpose of the Study:

• To investigate the psychometric properties of the CDR-FTLD using Rasch analysis.
• To assess the CDR-FTLD's sensitivity in distinguishing disease progression between FTLD and AD.
• To evaluate the CDR-FTLD's utility in clinical practice and research.

Main Methods:

• Rasch analysis was performed on the CDR-FTLD using data from the National Alzheimer Coordinating Center.
• A cohort of 603 patients (350 FTLD, 253 AD) was included for psychometric property verification and disease progression analysis.
• Longitudinal follow-up data over 24 months were analyzed to assess changes in dementia severity.

Main Results:

• The CDR-FTLD demonstrated good consistency, construct validity, and concurrent validity.
• FTLD patients showed greater dementia severity than AD patients at baseline, even after matching for cognitive status and disease duration.
• Rasch analyses revealed distinct patterns of disease progression in FTLD versus AD, with CDR-FTLD showing greater sensitivity to change than the mini-mental state examination (MMSE) at follow-up.

Conclusions:

• The CDR-FTLD is a valid and reliable measure for assessing dementia severity and change in FTLD.
• The scale effectively differentiates disease progression between FTLD and AD.
• Findings support the CDR-FTLD's use in clinical trials, prognosis, and patient care for FTLD.